Sales Revenue Exceeds Projections, BDI Pharma Demonstrates Continued Growth

COLUMBIA, SC–(Marketwire – July 15, 2010) –  BDI Pharma, Inc. (BDI), the nation’s fastest growing national distributor of biotech therapies, announced that, in spite of the uncertainty of the nation’s current economic climate, Sales Revenues continued to rise during the first two (2) fiscal quarters of 2010. This expansion of business represented an increase of fifteen percent (15%) above that for the same period in 2009 and exceeded the company’s forecasted growth for the first six (6) months of the year. The Specialty Biopharmaceutical class of products, primarily in the clinical areas of Oncology and Infectious Disease, served as the primary driver for Sales Revenue during this period. Also notable were gains within the Protein Biotherapeutics class, specific to the Hemophilia and Hyper-Immune product lines.

In addition, BDI Pharma realized significant growth in staffing through new hires during Q2 2010. Over the past ninety (90) days, the size of the company’s Biopharmaceutical Sales Staff grew by twenty percent (20%). The company also experienced growth within the BDI Promotions Division (the company’s Advertising and Promotional Division), as well as the Corporate Customer Service Division and established a new specialty sales division during the past quarter.

“Growth, at BDI Pharma, is not just an objective, it is an expectation and, as such, it is something for which we plan and prepare,” said William A. Shirey, III, Executive VP. “The key to BDI Pharma’s growth can be found in our commitment to incorporate a relatively simple matter — the strategic allocation of corporate resources — and to merge it with something far more difficult — the actual expense of those resources in a conscientious manner. Many companies adopt the former, but ultimately bend in response to market pressure and lose their will to integrate the latter. At BDI Pharma, we apply both with equal veracity as we strive to supply substantial, quantifiable value to our customers and manufacturing trade partners, alike.”

About BDI Pharma, Inc.

Since 1995, BDI Pharma, Inc. (formerly known as Blood Diagnostics, Inc.) has built an exceptional reputation as the industry trusted source for products and service. The company has exhibited an exemplary track record providing an unparalleled level of customer service, market data and product integrity to both its customer base and trade partners. Such commitment to the product channel has earned BDI recognition as “ADR,” or Authorized Distributor of Record, for the manufacturers it represents. BDI’s specialty pharmaceutical focus is evident in its commitment to biotherapeutics, chemotherapies, vaccines and plasma protein therapies, including albumin, IVIG, coagulation factors, high-titer immune globulins, and injectables. 

BDI Pharma defines its customer-centric approach to serving the nation’s healthcare community through innovative inventory supply solutions, unparalleled customer service, extensive product knowledge, 24/7 emergency availability and urgent need delivery. An open-access resource for reference material, educational literature, market data and online ordering, BDI Pharma’s home web page www.bdipharma.com has become an industry renowned point of reference. Proprietary programs for product consignment (www.consignadvantage.com), influenza vaccine pre-booking (www.securiflu.com), vaccine ordering (www.securivax.com) and purchasing/reward programs (www.qoreprogram.com and www.securigam.com) round out a family of solutions tailored to the needs of the healthcare community at large.